APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Acute Vulvovaginal Candidiasis Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Acute Vulvovaginal Candidiasis Treatment Market Analysis and Forecast 2026-2032

Report ID 173960390220 December 2025200 pages

Choose your research edition.

Industry ResearchAcute Vulvovaginal Candidiasis Treatment Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Acute Vulvovaginal Candidiasis Treatment Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Acute Vulvovaginal Candidiasis Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Acute Vulvovaginal Candidiasis Treatment Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Acute Vulvovaginal Candidiasis Treatment Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Acute Vulvovaginal Candidiasis Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Acute Vulvovaginal Candidiasis Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Acute Vulvovaginal Candidiasis Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Acute Vulvovaginal Candidiasis Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Acute Vulvovaginal Candidiasis Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Acute Vulvovaginal Candidiasis Treatment include Sandoz International GmbH, Novartis AG, Mylan N.V., Pfizer, Inc., Bayer AG., Scynexis, Inc, Phathom Pharmaceutical, Inc, Pacgen Life Science Corporation and NovaDigm Therapeutics, Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Acute Vulvovaginal Candidiasis Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Acute Vulvovaginal Candidiasis Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Acute Vulvovaginal Candidiasis Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Acute Vulvovaginal Candidiasis Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Acute Vulvovaginal Candidiasis Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Acute Vulvovaginal Candidiasis Treatment revenue, projected growth trends, production technology, application and end-user industry.

Acute Vulvovaginal Candidiasis Treatment Segment by Company

Sandoz International GmbH

Novartis AG

Mylan N.V.

Pfizer, Inc.

Bayer AG.

Scynexis, Inc

Phathom Pharmaceutical, Inc

Pacgen Life Science Corporation

NovaDigm Therapeutics, Inc

Mycovia Pharmaceuticals, Inc

Lupin

Grupo Ferrer Internacional, S.A

Cidara Therapeutics, Inc

Cadila Pharmaceuticals

Bristol-Myers Squibb Company

Basilea Pharmaceutica Ltd

Astellas Pharma Inc

Amplyx Pharmaceuticals Inc

Amneal Pharmaceuticals LLC

Accord Healthcare Ltd

Acute Vulvovaginal Candidiasis Treatment Segment by Type

Nystatin

Ketoconazole

Terconazole

Terbinafine

Clotrimazole

Fluconazole

Others

Acute Vulvovaginal Candidiasis Treatment Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Acute Vulvovaginal Candidiasis Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Vulvovaginal Candidiasis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acute Vulvovaginal Candidiasis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Vulvovaginal Candidiasis Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Acute Vulvovaginal Candidiasis Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Acute Vulvovaginal Candidiasis Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Acute Vulvovaginal Candidiasis Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Nystatin Major Player Table 3. Ketoconazole Major Player Table 4. Terconazole Major Player Table 5. Terbinafine Major Player Table 6. Clotrimazole Major Player Table 7. Fluconazole Major Player Table 8. Others Major Player Table 9. Global Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 10. Retail Pharmacies Major Player Table 11. Online Pharmacies Major Player Table 12. Hospital Pharmacies Major Player Table 13. Acute Vulvovaginal Candidiasis Treatment Industry Trends Table 14. Acute Vulvovaginal Candidiasis Treatment Industry Drivers Table 15. Acute Vulvovaginal Candidiasis Treatment Industry Opportunities and Challenges Table 16. Acute Vulvovaginal Candidiasis Treatment Industry Restraints Table 17. Global Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 18. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2021-2026) & (US$ Million) Table 19. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Region (2021-2026) Table 20. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2027-2032) & (US$ Million) Table 21. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Region (2027-2032) Table 22. Global Acute Vulvovaginal Candidiasis Treatment Revenue by Players (US$ Million) & (2021-2026) Table 23. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Players (2021-2026) Table 24. Global Acute Vulvovaginal Candidiasis Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Acute Vulvovaginal Candidiasis Treatment Key Players Headquarters & Area Served Table 26. Global Acute Vulvovaginal Candidiasis Treatment Players, Product Type & Application Table 27. Global Acute Vulvovaginal Candidiasis Treatment Players Establishment Date Table 28. Global Players Market Concentration Ratio (CR5 and HHI) Table 29. Global Acute Vulvovaginal Candidiasis Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 30. Global Acute Vulvovaginal Candidiasis Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 32. Global Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 33. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Type (2021-2026) Table 34. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Type (2027-2032) Table 35. Global Acute Vulvovaginal Candidiasis Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 37. Global Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 38. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Application (2021-2026) Table 39. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Application (2027-2032) Table 40. Sandoz International GmbH Company Information Table 41. Sandoz International GmbH Business Overview Table 42. Sandoz International GmbH Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Sandoz International GmbH Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 44. Sandoz International GmbH Recent Development Table 45. Novartis AG Company Information Table 46. Novartis AG Business Overview Table 47. Novartis AG Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Novartis AG Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 49. Novartis AG Recent Development Table 50. Mylan N.V. Company Information Table 51. Mylan N.V. Business Overview Table 52. Mylan N.V. Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Mylan N.V. Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 54. Mylan N.V. Recent Development Table 55. Pfizer, Inc. Company Information Table 56. Pfizer, Inc. Business Overview Table 57. Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 59. Pfizer, Inc. Recent Development Table 60. Bayer AG. Company Information Table 61. Bayer AG. Business Overview Table 62. Bayer AG. Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Bayer AG. Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 64. Bayer AG. Recent Development Table 65. Scynexis, Inc Company Information Table 66. Scynexis, Inc Business Overview Table 67. Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 69. Scynexis, Inc Recent Development Table 70. Phathom Pharmaceutical, Inc Company Information Table 71. Phathom Pharmaceutical, Inc Business Overview Table 72. Phathom Pharmaceutical, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Phathom Pharmaceutical, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 74. Phathom Pharmaceutical, Inc Recent Development Table 75. Pacgen Life Science Corporation Company Information Table 76. Pacgen Life Science Corporation Business Overview Table 77. Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 79. Pacgen Life Science Corporation Recent Development Table 80. NovaDigm Therapeutics, Inc Company Information Table 81. NovaDigm Therapeutics, Inc Business Overview Table 82. NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 84. NovaDigm Therapeutics, Inc Recent Development Table 85. Mycovia Pharmaceuticals, Inc Company Information Table 86. Mycovia Pharmaceuticals, Inc Business Overview Table 87. Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 89. Mycovia Pharmaceuticals, Inc Recent Development Table 90. Lupin Company Information Table 91. Lupin Business Overview Table 92. Lupin Acute Vulvovaginal Candidiasis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Lupin Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 94. Lupin Recent Development Table 95. Grupo Ferrer Internacional, S.A Company Information Table 96. Grupo Ferrer Internacional, S.A Business Overview Table 97. Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 99. Grupo Ferrer Internacional, S.A Recent Development Table 100. Cidara Therapeutics, Inc Company Information Table 101. Cidara Therapeutics, Inc Business Overview Table 102. Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 104. Cidara Therapeutics, Inc Recent Development Table 105. Cadila Pharmaceuticals Company Information Table 106. Cadila Pharmaceuticals Business Overview Table 107. Cadila Pharmaceuticals Acute Vulvovaginal Candidiasis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Cadila Pharmaceuticals Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 109. Cadila Pharmaceuticals Recent Development Table 110. Bristol-Myers Squibb Company Company Information Table 111. Bristol-Myers Squibb Company Business Overview Table 112. Bristol-Myers Squibb Company Acute Vulvovaginal Candidiasis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Bristol-Myers Squibb Company Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 114. Bristol-Myers Squibb Company Recent Development Table 115. Basilea Pharmaceutica Ltd Company Information Table 116. Basilea Pharmaceutica Ltd Business Overview Table 117. Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 119. Basilea Pharmaceutica Ltd Recent Development Table 120. Astellas Pharma Inc Company Information Table 121. Astellas Pharma Inc Business Overview Table 122. Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 124. Astellas Pharma Inc Recent Development Table 125. Amplyx Pharmaceuticals Inc Company Information Table 126. Amplyx Pharmaceuticals Inc Business Overview Table 127. Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 129. Amplyx Pharmaceuticals Inc Recent Development Table 130. Amneal Pharmaceuticals LLC Company Information Table 131. Amneal Pharmaceuticals LLC Business Overview Table 132. Amneal Pharmaceuticals LLC Acute Vulvovaginal Candidiasis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Amneal Pharmaceuticals LLC Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 134. Amneal Pharmaceuticals LLC Recent Development Table 135. Accord Healthcare Ltd Company Information Table 136. Accord Healthcare Ltd Business Overview Table 137. Accord Healthcare Ltd Acute Vulvovaginal Candidiasis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Accord Healthcare Ltd Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 139. Accord Healthcare Ltd Recent Development Table 140. North America Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 141. North America Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 142. North America Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 143. North America Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 144. North America Acute Vulvovaginal Candidiasis Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 145. North America Acute Vulvovaginal Candidiasis Treatment Revenue by Country (2021-2026) & (US$ Million) Table 146. North America Acute Vulvovaginal Candidiasis Treatment Revenue by Country (US$ Million) & (2027-2032) Table 147. Europe Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 148. Europe Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 149. Europe Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 150. Europe Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 151. Europe Acute Vulvovaginal Candidiasis Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 152. Europe Acute Vulvovaginal Candidiasis Treatment Revenue by Country (2021-2026) & (US$ Million) Table 153. Europe Acute Vulvovaginal Candidiasis Treatment Revenue by Country (US$ Million) & (2027-2032) Table 154. China Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 155. China Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 156. China Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 157. China Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 158. Asia Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 159. Asia Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 160. Asia Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 161. Asia Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 162. Asia Acute Vulvovaginal Candidiasis Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 163. Asia Acute Vulvovaginal Candidiasis Treatment Revenue by Region (US$ Million) & (2021-2026) Table 164. Asia Acute Vulvovaginal Candidiasis Treatment Revenue by Region (US$ Million) & (2027-2032) Table 165. SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 166. SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 167. SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 168. SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 169. SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 170. SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue by Country (2021-2026) & (US$ Million) Table 171. SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue by Country (US$ Million) & (2027-2032) Table 172. Research Programs/Design for This Report Table 173. Authors List of This Report Table 174. Secondary Sources Table 175. Primary Sources List of Figures Figure 1. Acute Vulvovaginal Candidiasis Treatment Image Figure 2. Global Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Acute Vulvovaginal Candidiasis Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Nystatin Image Figure 5. Ketoconazole Image Figure 6. Terconazole Image Figure 7. Terbinafine Image Figure 8. Clotrimazole Image Figure 9. Fluconazole Image Figure 10. Others Image Figure 11. Global Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Acute Vulvovaginal Candidiasis Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 13. Retail Pharmacies Image Figure 14. Online Pharmacies Image Figure 15. Hospital Pharmacies Image Figure 16. Global Acute Vulvovaginal Candidiasis Treatment Market Size (US$ Million) & (2021-2032) Figure 17. Global Acute Vulvovaginal Candidiasis Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 19. Global Acute Vulvovaginal Candidiasis Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Type (2021-2032) Figure 24. Global Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 26. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Application (2021-2032) Figure 27. North America Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 28. North America Acute Vulvovaginal Candidiasis Treatment Revenue Share by Type (2021-2032) Figure 29. North America Acute Vulvovaginal Candidiasis Treatment Revenue Share by Application (2021-2032) Figure 30. North America Acute Vulvovaginal Candidiasis Treatment Revenue Share by Country (2021-2032) Figure 31. United States Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Canada Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Mexico Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Europe Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 35. Europe Acute Vulvovaginal Candidiasis Treatment Revenue Share by Type (2021-2032) Figure 36. Europe Acute Vulvovaginal Candidiasis Treatment Revenue Share by Application (2021-2032) Figure 37. Europe Acute Vulvovaginal Candidiasis Treatment Revenue Share by Country (2021-2032) Figure 38. Germany Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. France Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. U.K. Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Italy Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Spain Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Russia Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Netherlands Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Nordic Countries Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. China Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. China Acute Vulvovaginal Candidiasis Treatment Revenue Share by Type (2021-2032) Figure 48. China Acute Vulvovaginal Candidiasis Treatment Revenue Share by Application (2021-2032) Figure 49. Asia Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 50. Asia Acute Vulvovaginal Candidiasis Treatment Revenue Share by Type (2021-2032) Figure 51. Asia Acute Vulvovaginal Candidiasis Treatment Revenue Share by Application (2021-2032) Figure 52. Asia Acute Vulvovaginal Candidiasis Treatment Revenue Share by Region (2021-2032) Figure 53. Japan Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. South Korea Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. India Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Australia Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Taiwan Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Southeast Asia Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 60. SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue Share by Type (2021-2032) Figure 61. SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue Share by Application (2021-2032) Figure 62. SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue Share by Country (2021-2032) Figure 63. Brazil Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Argentina Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Chile Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Colombia Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Peru Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Saudi Arabia Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Israel Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. UAE Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Turkey Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Iran Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Egypt Acute Vulvovaginal Candidiasis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Nystatin
  • Ketoconazole
  • Terconazole
  • Terbinafine
  • Clotrimazole
  • Fluconazole
  • Others
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Sandoz International GmbH
  • Novartis AG
  • Mylan N.V.
  • Pfizer, Inc.
  • Bayer AG.
  • Scynexis, Inc
  • Phathom Pharmaceutical, Inc
  • Pacgen Life Science Corporation
  • NovaDigm Therapeutics, Inc
  • Mycovia Pharmaceuticals, Inc
  • Lupin
  • Grupo Ferrer Internacional, S.A
  • Cidara Therapeutics, Inc
  • Cadila Pharmaceuticals
  • Bristol-Myers Squibb Company
  • Basilea Pharmaceutica Ltd
  • Astellas Pharma Inc
  • Amplyx Pharmaceuticals Inc
  • Amneal Pharmaceuticals LLC
  • Accord Healthcare Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Acute Vulvovaginal Candidiasis Treatment Market by Type
  3. 1.2.1 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Nystatin
  5. 1.2.3 Ketoconazole
  6. 1.2.4 Terconazole
  7. 1.2.5 Terbinafine
  8. 1.2.6 Clotrimazole
  9. 1.2.7 Fluconazole
  10. 1.2.8 Others
  11. 1.3 Acute Vulvovaginal Candidiasis Treatment Market by Application
  12. 1.3.1 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Application, 2021 VS 2025 VS 2032
  13. 1.3.2 Retail Pharmacies
  14. 1.3.3 Online Pharmacies
  15. 1.3.4 Hospital Pharmacies
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Acute Vulvovaginal Candidiasis Treatment Market Dynamics
  1. 2.1 Acute Vulvovaginal Candidiasis Treatment Industry Trends
  2. 2.2 Acute Vulvovaginal Candidiasis Treatment Industry Drivers
  3. 2.3 Acute Vulvovaginal Candidiasis Treatment Industry Opportunities and Challenges
  4. 2.4 Acute Vulvovaginal Candidiasis Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Acute Vulvovaginal Candidiasis Treatment Market Perspective (2021-2032)
  2. 3.2 Global Acute Vulvovaginal Candidiasis Treatment Growth Trends by Region
  3. 3.2.1 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Acute Vulvovaginal Candidiasis Treatment Revenue by Players
  2. 4.1.1 Global Acute Vulvovaginal Candidiasis Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Acute Vulvovaginal Candidiasis Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Acute Vulvovaginal Candidiasis Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Acute Vulvovaginal Candidiasis Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Acute Vulvovaginal Candidiasis Treatment Players, Product Type & Application
  8. 4.5 Global Acute Vulvovaginal Candidiasis Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Acute Vulvovaginal Candidiasis Treatment Market CR5 and HHI
  11. 4.6.3 2025 Acute Vulvovaginal Candidiasis Treatment Tier 1, Tier 2, and Tier 3
5 Acute Vulvovaginal Candidiasis Treatment Market Size by Type
  1. 5.1 Global Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Type (2021-2032)
6 Acute Vulvovaginal Candidiasis Treatment Market Size by Application
  1. 6.1 Global Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sandoz International GmbH
  2. 7.1.1 Sandoz International GmbH Company Information
  3. 7.1.2 Sandoz International GmbH Business Overview
  4. 7.1.3 Sandoz International GmbH Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sandoz International GmbH Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  6. 7.1.5 Sandoz International GmbH Recent Developments
  7. 7.2 Novartis AG
  8. 7.2.1 Novartis AG Company Information
  9. 7.2.2 Novartis AG Business Overview
  10. 7.2.3 Novartis AG Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis AG Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  12. 7.2.5 Novartis AG Recent Developments
  13. 7.3 Mylan N.V.
  14. 7.3.1 Mylan N.V. Company Information
  15. 7.3.2 Mylan N.V. Business Overview
  16. 7.3.3 Mylan N.V. Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Mylan N.V. Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  18. 7.3.5 Mylan N.V. Recent Developments
  19. 7.4 Pfizer, Inc.
  20. 7.4.1 Pfizer, Inc. Company Information
  21. 7.4.2 Pfizer, Inc. Business Overview
  22. 7.4.3 Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  24. 7.4.5 Pfizer, Inc. Recent Developments
  25. 7.5 Bayer AG.
  26. 7.5.1 Bayer AG. Company Information
  27. 7.5.2 Bayer AG. Business Overview
  28. 7.5.3 Bayer AG. Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Bayer AG. Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  30. 7.5.5 Bayer AG. Recent Developments
  31. 7.6 Scynexis, Inc
  32. 7.6.1 Scynexis, Inc Company Information
  33. 7.6.2 Scynexis, Inc Business Overview
  34. 7.6.3 Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  36. 7.6.5 Scynexis, Inc Recent Developments
  37. 7.7 Phathom Pharmaceutical, Inc
  38. 7.7.1 Phathom Pharmaceutical, Inc Company Information
  39. 7.7.2 Phathom Pharmaceutical, Inc Business Overview
  40. 7.7.3 Phathom Pharmaceutical, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Phathom Pharmaceutical, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  42. 7.7.5 Phathom Pharmaceutical, Inc Recent Developments
  43. 7.8 Pacgen Life Science Corporation
  44. 7.8.1 Pacgen Life Science Corporation Company Information
  45. 7.8.2 Pacgen Life Science Corporation Business Overview
  46. 7.8.3 Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  48. 7.8.5 Pacgen Life Science Corporation Recent Developments
  49. 7.9 NovaDigm Therapeutics, Inc
  50. 7.9.1 NovaDigm Therapeutics, Inc Company Information
  51. 7.9.2 NovaDigm Therapeutics, Inc Business Overview
  52. 7.9.3 NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  54. 7.9.5 NovaDigm Therapeutics, Inc Recent Developments
  55. 7.10 Mycovia Pharmaceuticals, Inc
  56. 7.10.1 Mycovia Pharmaceuticals, Inc Company Information
  57. 7.10.2 Mycovia Pharmaceuticals, Inc Business Overview
  58. 7.10.3 Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  60. 7.10.5 Mycovia Pharmaceuticals, Inc Recent Developments
  61. 7.11 Lupin
  62. 7.11.1 Lupin Company Information
  63. 7.11.2 Lupin Business Overview
  64. 7.11.3 Lupin Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Lupin Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  66. 7.11.5 Lupin Recent Developments
  67. 7.12 Grupo Ferrer Internacional, S.A
  68. 7.12.1 Grupo Ferrer Internacional, S.A Company Information
  69. 7.12.2 Grupo Ferrer Internacional, S.A Business Overview
  70. 7.12.3 Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  72. 7.12.5 Grupo Ferrer Internacional, S.A Recent Developments
  73. 7.13 Cidara Therapeutics, Inc
  74. 7.13.1 Cidara Therapeutics, Inc Company Information
  75. 7.13.2 Cidara Therapeutics, Inc Business Overview
  76. 7.13.3 Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  78. 7.13.5 Cidara Therapeutics, Inc Recent Developments
  79. 7.14 Cadila Pharmaceuticals
  80. 7.14.1 Cadila Pharmaceuticals Company Information
  81. 7.14.2 Cadila Pharmaceuticals Business Overview
  82. 7.14.3 Cadila Pharmaceuticals Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Cadila Pharmaceuticals Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  84. 7.14.5 Cadila Pharmaceuticals Recent Developments
  85. 7.15 Bristol-Myers Squibb Company
  86. 7.15.1 Bristol-Myers Squibb Company Company Information
  87. 7.15.2 Bristol-Myers Squibb Company Business Overview
  88. 7.15.3 Bristol-Myers Squibb Company Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Bristol-Myers Squibb Company Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  90. 7.15.5 Bristol-Myers Squibb Company Recent Developments
  91. 7.16 Basilea Pharmaceutica Ltd
  92. 7.16.1 Basilea Pharmaceutica Ltd Company Information
  93. 7.16.2 Basilea Pharmaceutica Ltd Business Overview
  94. 7.16.3 Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  96. 7.16.5 Basilea Pharmaceutica Ltd Recent Developments
  97. 7.17 Astellas Pharma Inc
  98. 7.17.1 Astellas Pharma Inc Company Information
  99. 7.17.2 Astellas Pharma Inc Business Overview
  100. 7.17.3 Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  102. 7.17.5 Astellas Pharma Inc Recent Developments
  103. 7.18 Amplyx Pharmaceuticals Inc
  104. 7.18.1 Amplyx Pharmaceuticals Inc Company Information
  105. 7.18.2 Amplyx Pharmaceuticals Inc Business Overview
  106. 7.18.3 Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  108. 7.18.5 Amplyx Pharmaceuticals Inc Recent Developments
  109. 7.19 Amneal Pharmaceuticals LLC
  110. 7.19.1 Amneal Pharmaceuticals LLC Company Information
  111. 7.19.2 Amneal Pharmaceuticals LLC Business Overview
  112. 7.19.3 Amneal Pharmaceuticals LLC Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Amneal Pharmaceuticals LLC Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  114. 7.19.5 Amneal Pharmaceuticals LLC Recent Developments
  115. 7.20 Accord Healthcare Ltd
  116. 7.20.1 Accord Healthcare Ltd Company Information
  117. 7.20.2 Accord Healthcare Ltd Business Overview
  118. 7.20.3 Accord Healthcare Ltd Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Accord Healthcare Ltd Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  120. 7.20.5 Accord Healthcare Ltd Recent Developments
8 North America
  1. 8.1 North America Acute Vulvovaginal Candidiasis Treatment Revenue (2021-2032)
  2. 8.2 North America Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Acute Vulvovaginal Candidiasis Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Acute Vulvovaginal Candidiasis Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Acute Vulvovaginal Candidiasis Treatment Revenue by Country
  11. 8.6.1 North America Acute Vulvovaginal Candidiasis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Acute Vulvovaginal Candidiasis Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Acute Vulvovaginal Candidiasis Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Acute Vulvovaginal Candidiasis Treatment Revenue (2021-2032)
  2. 9.2 Europe Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Acute Vulvovaginal Candidiasis Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Acute Vulvovaginal Candidiasis Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Acute Vulvovaginal Candidiasis Treatment Revenue by Country
  11. 9.6.1 Europe Acute Vulvovaginal Candidiasis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Acute Vulvovaginal Candidiasis Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Acute Vulvovaginal Candidiasis Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Acute Vulvovaginal Candidiasis Treatment Revenue (2021-2032)
  2. 10.2 China Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2027-2032)
  5. 10.3 China Acute Vulvovaginal Candidiasis Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2027-2032)
  9. 10.5 China Acute Vulvovaginal Candidiasis Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Acute Vulvovaginal Candidiasis Treatment Revenue (2021-2032)
  2. 11.2 Asia Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Acute Vulvovaginal Candidiasis Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Acute Vulvovaginal Candidiasis Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Acute Vulvovaginal Candidiasis Treatment Revenue by Country
  11. 11.6.1 Asia Acute Vulvovaginal Candidiasis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Acute Vulvovaginal Candidiasis Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Acute Vulvovaginal Candidiasis Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue by Country
  11. 12.6.1 SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Acute Vulvovaginal Candidiasis Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst